CALCOBUTROL
Molecular Excipient
| Mwt. | LogP | HBD | HBA | PSA | RB | CSP3 |
|---|---|---|---|---|---|---|
| 450.0 | -3.8 | 6 | 10 | 186.0 | 10 | 0.83 |
- CAS
- 151878238
- UNII
- J1A8830GE7
- SYNONYMS
-
- ZINC ID(s)
- Availability
- Present in 10 ZINC catalogs
Known Active Genes
There has not been any activity reported at 10μM or less for this excipient (per ChEBML)
Clinical Trials
This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
| Code | Date | Title | Phase | Status |
|---|---|---|---|---|
| NCT02350426 | 2015-04-01 | A Study to Assess Inflammation in Rheumatoid Arthritis Using Molecular Imaging Techniques | Phase 1 | Not Yet Recruiting |
| NCT02274246 | 2014-11-01 | Validation of the Efficacy of the Tool GIMIAS® for the Assessment of Left Atrial Fibrosis in a Group of Healthy Volunteers (RESTORE-HV) | Phase 1 | Recruiting |
| NCT02135861 | 2014-07-01 | A Method Validation Study for Evaluation of Novel Treatments Limiting Pulmonary Oedema in Cardiac Failure | Phase 1 | Recruiting |
| NCT01890434 | 2013-08-01 | Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD) Including GSPECT (Gated Single Photon Emission Computed Tomography) | Phase 3 | Recruiting |
| NCT01890421 | 2013-07-01 | Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD) | Phase 3 | Recruiting |
| NCT01660841 | 2012-09-01 | Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging | Phase 3 | Completed |
| NCT01655290 | 2012-08-01 | Comparison of Gadobutrol and Gadobenate Dimeglumin for Delayed Enhancement Cardiac MRI | Phase 2 | Active, Not Recruiting |
| NCT01613417 | 2012-08-01 | Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain | Phase 4 | Completed |
| NCT01544166 | 2012-05-01 | Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive) | Phase 1 | Completed |
| NCT01344447 | 2011-05-01 | Gadobutrol Enhanced MRA of the Supra-aortic Vessels | Phase 3 | Completed |
| NCT01344460 | 2011-05-01 | Gadobutrol Enhanced MRA of the Renal Arteries | Phase 3 | Completed |
| NCT01104584 | 2010-05-01 | Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI) | Phase 3 | Completed |
| NCT01067976 | 2010-02-01 | Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI | Phase 3 | Completed |
| NCT01050829 | 2010-01-01 | Gadobutrol Magnevist-controlled Body Study | Phase 3 | Completed |
| NCT00828737 | 2008-12-01 | Safety of Gadovist in Renally Impaired Patients | Phase 4 | Completed |
| NCT00709852 | 2008-06-01 | Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging | Phase 3 | Completed |
| NCT00764387 | 2008-03-01 | Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions. | Phase 4 | Completed |
| NCT00623467 | 2007-12-01 | Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging | Phase 3 | Completed |
| NCT00522951 | 2007-08-01 | SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study | Phase 3 | Completed |
| NCT00468819 | 2007-05-01 | A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children | Phase 1 | Completed |
| NCT00395733 | 2006-10-01 | Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients | Phase 3 | Completed |
| NCT00395460 | 2006-09-01 | Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients | Phase 3 | Completed |
| NCT00862459 | 2005-08-01 | Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) | Phase 2 | Completed |
| NCT01490294 | 2004-03-01 | Myocardial Perfusion MRI | Phase 2 | Completed |